IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis drug, Briumvi. The post IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug appeared first on Investor's Business Daily.
TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis drug, Briumvi.
The post IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
